AI-powered exoskeletons are revolutionizing mobility for paralyzed patients, promising a future where walking again is not just a dream but a tangible reality.
Story Snapshot
- Wandercraft’s exoskeletons help paralyzed patients walk, transitioning from clinical to home use.
- The first self-balancing, hands-free exoskeleton for home use is being developed.
- Clinical trials are underway in the U.S. with anticipated FDA submission for home-use devices.
- Key partnerships are driving innovation and cost efficiency in exoskeleton technology.
Exoskeleton Technology Transforming Mobility
Wandercraft, a French robotics company, is pioneering the development of AI-powered exoskeletons designed to restore natural walking ability to individuals with severe mobility impairments. This innovative technology recently enabled Caroline Laubach, paralyzed from the waist down, to rise from her wheelchair and walk again. The company’s exoskeletons, including the Atalante model, are gaining traction in the U.S. market, with ongoing clinical trials aimed at bringing these devices into homes across America.
AI-powered exoskeletons are helping paralyzed patients walk again — and could soon be coming to homes across the U.S. https://t.co/vtbE3Vm0yM pic.twitter.com/S9fWyVyfUF
— New York Post (@nypost) July 31, 2025
The Atalante exoskeleton is the first to offer hands-free, self-balancing walking capabilities, a significant advancement over earlier models that required crutches or walkers. This breakthrough is facilitated by advanced AI and robotics, enabling real-time adaptation and enhanced safety. Wandercraft’s expansion into the U.S. includes a new headquarters in New York and partnerships with leading technology and manufacturing companies, such as Nvidia and Renault Group, to streamline development and reduce costs.
Watch: Paralyzed woman uses exoskeleton to walk again
Clinical Trials and U.S. Expansion
Wandercraft’s clinical trials for the home-use Personal Exoskeleton, named Eve, are currently underway in the U.S., with first patients enrolled in early 2025. The company aims to submit for FDA clearance once trials are completed. The device was showcased at the 2024 Olympic and Paralympic Torch Relay, highlighting its potential to transform mobility for individuals with disabilities. This move marks a critical step in making upright mobility accessible to millions, aligning with the company’s mission to improve quality of life for those with mobility challenges.
The U.S. has a significant population of individuals with spinal cord injuries and strokes, creating a growing demand for innovative mobility solutions. Wandercraft’s exoskeletons offer a promising solution, providing independence and improved rehabilitation outcomes for users. As the company prepares for FDA submission, the prospect of Medicare coverage further enhances the accessibility and potential impact of these devices.
Sources:
First patients join study of Wandercraft home-use exoskeleton
Nvidia blog on AI-powered exoskeletons
Wandercraft showcases self-balancing exoskeleton at 2024 Olympics
Robotics industry guides
